Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 956-966

  Goyal, Bhoomika R ^a   Parmar, Kaushal ^a   Goyal, Ramesh K ^a   Mehta, Anita A ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

Cardiac hypertrophy; Cardiovascular complications; Telmisartan; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CATALASE; COLLAGEN; CREATINE KINASE; CREATININE; GLUTATHIONE; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TELMISARTAN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART VENTRICLE HYPERTROPHY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RAT; STREPTOZOCIN DIABETES; TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80051633992     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70611-9     Document Type: Article

References (74)

1. Aeibi H, Bergmeyer H: Methods in Enzymatic Analysis, 2nd edn., Academic Press, New York, 1974, 673.
2. Alexander RW: Inflammation and coronary artery disease. N Engl J Med, 1994, 331, 468-469.
3. Asbun J, Manso AM, Villarreal FJ: Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. Am J Physiol Heart Circ Physiol, 2005, 288, H227-H234. (Pubitemid 40023851)
4. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581. (Pubitemid 34517204)
5. Benson SC, Pershadsingh HA, Ho C, Chittiboyina A, Desai P, Pravenec M, Qi N et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension, 2004, 43, 993-1002. (Pubitemid 38579904)
6. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med, 2002, 53, 409-435. (Pubitemid 34177889)
7. Berry C, Hamilton CA, Brosnan J, Magill FG, Berg GA, McMurray JJV, Dominiczak AF: Investigation into the sources of superoxide in human blood vessels, angiotensin II increases superoxide production in human internal mammary arteries. Circulation, 2000, 101, 2206-2212. (Pubitemid 30253051)
8. Beutler E, Duron O, Kelly B: Reduced glutathione estimation. J Lab Clin Med, 1963, 61, 882.
9. Bhakdi S, Toprzewski M, Klouche M, Hemmes M: Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhance complement activation. Arterioscler Thromb Vasc Biol, 1999, 19, 2348-2354. (Pubitemid 29477835)
10. Bonora E, Zavarai I, Coscelli C, Butturini U: Decreased hepatic insulin excretion in subjects with mild glucose intolerance. Metabolism, 1983, 32, 438-444.
11. 2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol, 1995, 76, 8D-13D.
12. Carr AA, Prisant LM, Watkins LO: Detection of hypertensive left ventricular hypertrophy. Hypertension, 1985, 7, 948-954. (Pubitemid 16147477)
13. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, Eisenbarth GS, Rewers M: Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes, 2004, 53, 2569-2573. (Pubitemid 39299263)
14. Dahm K, Tikellis C, Reid CM, Johnston CI, Cooper ME: Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens, 2005, 23, 463-473. (Pubitemid 40684700)
15. De Beer FC, Hind CRK, Fox KM, Allan R, Maseri A, Pepys MB: Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J, 1982, 47, 239-243. (Pubitemid 12179920)
16. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR et al.: Impact of diabetes on cardiac structure and function: the strong heart study. Circulation, 2000, 101, 2271-2276. (Pubitemid 30317129)
17. Evans JL, Maddux BA, Goldfine ID: The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal, 2005, 7, 1040-1052. (Pubitemid 40967154)
18. Fujimoto WY: The importance of insulin resistance in the pathogenesis of type 2 diabete mellitus. Am J Med, 2000, 108, 9S-14S.
19. Funakawa S: Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats. Eur J Pharmacol, 1983, 94, 27-33.
20. Goebel M, Clemenz M, Unger T: Effective treatment of hypertension by AT 1 receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther, 2006, 4, 615-620.
21. Goyal BR, Mesariya P, Goyal R K, Mehta AA: Effect of telmisartan on cardiovascular complications associated with STZ-diabetic rats. Mol Cell Biochem, 2008, 314, 123-131.
22. Goyal BR, Solanki N, Goyal RK, Mehta AA: Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol, 2009, 54, 502-509.
23. Goyal RK: Hyperinsulinemia and insulin resistance in hypertension: Differential effects of antihypertensive agents. Clin Exper Hypertens, 1999, 21, 167-179.
24. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis risk in communities study. N Engl J Med, 2000, 342, 905-912. (Pubitemid 30177050)
25. Huang E, Kuo W, Chen Y, Chen T, Chang M, Lu M, Tzang B et al.: Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta, 2006, 366, 293-298. (Pubitemid 43330998)
26. Ilercil A, Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK et al.: Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes, 2002, 51, 1543-1547. (Pubitemid 34826623)
27. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T et al.: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000, 49, 1939-1945.
28. Jesmin S, Sakuma I, Hattori Y, Kitabatake A: Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol, 2003, 23, 2021-2026. (Pubitemid 37433195)
29. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD: Matrix metalloproteinases and diabetic vascular complications. Angiology, 2005, 56, 173-189. (Pubitemid 40404472)
30. Kakuta H, Sudoh K, Sasamatsu M, Yamagishi S: Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor blockers. Int J Clin Pharm Res, 2005, 25, 41-46.
31. Kamari Y, Harari A, Shaish A, Peleg E, Sharabi Y, Harats D, Grossman E: Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertens Res, 2008, 31, 135-140. (Pubitemid 351325625)
32. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation, 2000, 101, 1130-1137. (Pubitemid 30146614)
33. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE: Effects of high-density lipoprotein on acetylcholine induced coronary vasoreactivity. Am J Cardiol, 1991, 68, 1425-1430.
34. Lang D, Mosfer SI, Shakesby A, Donaldson F, Lewis MJ: Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: the role of angiotensin II. Circ Res, 2000, 86, 463-469. (Pubitemid 30141766)
35. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL: Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res, 1999, 84, 1043-1049. (Pubitemid 29227683)
36. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, et al: The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the strong heart study. J Am Coll Cardiol, 2001, 37, 1943-1949. (Pubitemid 32499984)
37. 2 receptors in cardiac hypertrophy and disease. Am J Cardiol, 1999, 83, Suppl 1, 48-52.
38. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R et al.: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens, 2001, 19, 1167-1176. (Pubitemid 32493652)
39. Martina B, Dieterle T, Sigle JP, Surber C, Battegay E: Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension: a randomized, double-blind trial. Cardiology, 2003, 99, 169-170. (Pubitemid 36736961)
40. Misra HP, Frodvich I: The role of superoxide anion autoxidation of epinephrine and a simple method for superoxide dismutase. J Biol Chem, 1984, 247, 3170-3175.
41. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H: Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation, 2000, 101, 899-907. (Pubitemid 30117886)
42. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M: Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation, 1998, 98, 794-799. (Pubitemid 28391845)
43. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem, 1979, 95, 351-358. (Pubitemid 9194347)
44. Oliveira DR, Santos RA, Santos GF, Khosla MC, Campagnole-Santos MJ: Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension, 1996, 27, 1284-1290. (Pubitemid 26165632)
45. ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med, 2008, 358, 1547-1559.
46. Pershadsingh HA, Benson SC, Ho CI, Avery MA, Kurtz TW: Identification of PPAR-γ activators that do not promote fluid retention and edema: implications for treating insulin resistant hypertension and the metabolic syndrome. In: Proceedings of the Endocrine Society Symposium on Nuclear Receptors in Cardiovascular Disease, Hot Topics in Endocrinology. San Diego, California, 2003, Abstract 29.
47. Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res, 2005, 33, 39A-49A. (Pubitemid 41397908)
48. Portha B, Picon L, Rosselin G: Chemical diabetes in the adult rats as the spontaneous evolution of neonatal diabetes. Diabetologia, 1979, 17, 371-377. (Pubitemid 10219170)
49. Pradhan A, Manson J, Rifai N, Buring J, Ridker P: C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA, 2001, 286, 327-334. (Pubitemid 32656163)
50. Prockop DJ, Udenfriend S: A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem, 1960, 1, 228-239.
51. Rahimi R, Nikfar S, Larijani B, Abdollahi M: A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother, 2005, 59, 365-373. (Pubitemid 41219650)
52. Rani SH, Rao DV, Prakash SM, Jyothy A: Serum adenosine deaminase activity and C-reactive protein levels in unstable angina. Indian J Hum Gen, 2003, 9, 17-20.
53. Roberts R, Sobel BE: Creatine kinase isoenzymes in the assessment of heart disease. Am Heart J, 1978, 95, 521-528. (Pubitemid 8314425)
54. Setaro JF: The hypertensive heart: new observations and evolving therapeutic imperatives. J Clin Hypertens (Greenwich), 2001, 3, 14-15.
55. Sheen J: Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 2004, 64, 2537-2565.
56. Smits JFM, Krimpen C, Schoemaker RG, Cleutjenws JPM, Daemen MJAP: Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol, 1992, 20, 772-778.
57. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension, 2001, 37, 1053-1068.
58. Sowers JR, Zemel MB: Clinical implications of hypertension in the diabetic patient: A review. Am J Hypertens, 1990, 3, 415-424. (Pubitemid 20188298)
59. Stehouwer CDA, Schaper NC: The pathogenesis of vascular complications of diabetes mellitus: one voice or many? Eur J Clin Invest, 1996, 26, 535-543. (Pubitemid 26291902)
60. 1 and repair in the infarcted heart. J Mol Cell Cardiol, 1995, 30, 1559-1569.
61. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T: Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol, 2006, 41, 989-997. (Pubitemid 44791331)
62. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, 2008, 372, 1174-1183.
63. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317, 703-712.
64. van Harsdorf R, Li PF, Dietz R: Signalling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation, 1999, 99, 2934-2941.
65. Wang X, Ren B, Liu S, Sentex E, Tappia PS, Dhalla NS: Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol, 2003, 94, 752-763. (Pubitemid 36158255)
66. Weber KT, Sun Y, Campbell SE: Structural remodelling of the heart by fibrous tissue: Role of circulating hormones and local produced peptides. Eur Heart J, 1995, 16, 12-18. (Pubitemid 26082316)
67. Weir MR: Diabetes and hypertension: blood pressure control and consequences. Am J Hypertens, 1999, 12, 170S-178S.
68. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T et al.: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem, 2001, 276, 41245-41254.
69. Yoshida S, Yamsgishi K, Nakamura T, Matsui T, Imaizumi M, Takeuchi H, Koga T et al.: Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferators activated receptor-gamma activation. Diabetologia, 2006, 49, 3094-3099. (Pubitemid 44730314)
70. 1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol, 2007, 42, 804-811.
71. Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS: Pentoxifylline attenuates cardiac dysfunction and reduces TNF-α level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol, 2005, 289, H832-H839. (Pubitemid 41129401)
72. Zhao W, Ahokas RA, Weber KT, Sun Y: ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol, 2006, 291, H336-H343.
73. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part II. Causal mechanisms and treatment. Circulation, 2002, 105, 1503-1508. (Pubitemid 34263285)
74. Zou Z, Xi GL, Yuan HB, Zhu QF, Shi XY: Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens, 2009, 23, 339-349.